Nervous System Diseases

1,005 trials 421 recruiting

Filter these 1,005 trials by phase, country and sponsor.

Open in Search →

Add-on Clioquinol in drug-resistant epilepsy: an exploratory study Recruiting

2024-511388-27-04 Drug resistant epilepsy 4 2024-07-16
A clinical trial to learn how an investigational drug (MP-101) affects on the laboratory signs of the disease when given to Amyotrophic Late… Recruiting

2023-507195-43-00 Amyotrophic Lateral Sclerosis (ALS) 3 2024-07-01
Longitudinal multicenter head-to-head harmonization of tau PET tracers (HEAD Study) Recruiting

2023-510508-31-01 cognitive impairment 4 2024-07-01
Efficacy of perioperative duloxetine in patients at high risk for developing chronic postsurgical pain after inguinal hernia repair: a multi… Recruiting

2023-505860-12-00 Chronic postsurgical pain after inguinal hernia repair 5 2024-06-26
TRAUMACELL - Effects of intravascular administration of mesenchymal stromal cells derived from Wharton’s Jelly of the umbilical cord on syst… Recruiting

2023-504415-33-00 Patients aged 15 years and 3 months and older with seve 9 2024-06-25
A study to learn if rozanolixizumab is safe, how it moves through the body, and if it works in children with myasthenia gravis Recruiting

2022-502074-16-00 Generalized Myasthenia Gravis 10 2024-06-14
A Placebo-Controlled, Randomized Double-Blind Parallel Group 12-Month Trial of Fasudil for the Treatment of Early Alzheimer’s Disease Recruiting

2023-506514-44-00 Alzheimer's disease 4 2024-06-11
Pathophysiology of pain in Parkinson's disease: exploration of the serotonin system in positron emission tomography Recruiting

2022-501123-24-00 Parkinson's disease 4 2024-06-10
Multicentric trial on the use of combined therapy of Thiamine and biotine in patients with Huntington´s disease. Recruiting

2023-508637-14-00 Huntington´s disease. 9 2024-06-06
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Nervous system diseases 5 2024-05-20
Atorvastatin in episodic migraine Recruiting

2022-502176-23-01 Migraine 4 2024-05-13
Atorvastatin in chronic migraine (StainMigChronic) Recruiting

2022-502177-42-02 Chronic migraine 4 2024-05-13
A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w… Recruiting

2023-504151-27-00 Psychosis associated with Alzheimer’s Disease 5 2024-05-09
SMART-MS Recruiting

2023-510228-63-00 Multiple sclerosis 4 2024-05-01
A Study to Investigate the Pharmacokinetics (PK) and Safety of Risdiplam in Infants with Spinal Muscular Atrophy Recruiting

2023-505602-42-00 Spinal Muscular Atrophy (SMA) 4 2024-04-30
Psilocybin for hospitalized patients with treatment-resistant depression Recruiting

2022-501857-35-00 treatment-resistant depression 4 2024-04-22
Evaluation of the efficacy and safety of Rituximab in patients with Amyotrophic Lateral Sclerosis (ALS) Recruiting

2022-502743-35-00 Sporadic Amyotrophic Lateral Sclerosis 4 2024-04-22
Clinical study to assess the efficacy and safety of Cannabidiol in children and young adults with rare disease-associated severe epilepsy Recruiting

2023-503709-12-00 Epilepsy 4 2024-04-12
A Placebo-controlled Study to Evaluate the Efficacy and Safety of Clenbuterol in Patients with Spinal and Bulbar Muscular Atrophy (SBMA) Recruiting

2024-516563-86-00 Spinal and Bulbar Muscular Atrophy 4 2024-04-11
Phase 1b Study of ION356 to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics in Patients with Pelizaeus-Merzbacher Disease Recruiting

2022-502432-39-00 Pelizaeus-Merzbacher Disease 1 2024-04-10
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1076986 in Healthy Adults. Recruiting

2023-508305-24-00 Movement disorders 1 2024-03-29
An Open-Label Exploratory Study of Fosigotifator in Subjects with Vanishing White Matter Disease Recruiting

2023-505704-30-00 Vanishing White Matter disease 9 2024-03-22
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA) Recruiting

2023-504472-24-00 Early Idiopathic Parkinson’s disease (PD) 4 2024-03-19
Multicenter, open-label, phase II study in patients with immunoglobulin M monoclonal gammopathy of unknown significance and Myelin Associate… Recruiting

2023-505933-29-00 IgM monoclonal gammopathy of unknown significance (MGUS 4 2024-03-13